Norway· NO-ID_98C7CED1-B884-4F64-AF49-DA97949BFCE2
Alprolix
A coagulation factor ix product containing eftrenonacog alfa, registered in Norway by Swedish Orphan Biovitrum International AB. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix is registered in 12 of 19 countries.
Countries holding a registration under ATC B02BD04 (coagulation factor ix), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Coagulation factor ix · ATC B02BD04
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Eftrenonacog Alfa
- Manufacturer
- Swedish Orphan Biovitrum International AB
- Country
- Norway (NO)
- ATC code
- B02BD04
- ATC class
- Coagulation factor IX
- Defined daily dose
- 600 E, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_varenummer4563251NOK 43430
- gtin7350031441116
- no_merkevare_idID_98C7CED1-B884-4F64-AF49-DA97949BFCE2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor ix in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAlprolix 3000 IUSwedish Orphan Biovitrum (Publ)
- PolandAlprolixSwedish Orphan Biovitrum AB
- SwedenALPROLIX 3000 IE Pulver och vätska till injektionsvätska, lösningSwedish Orphan Biovitrum AB (publ)
- Japanエフトレノナコグ アルファ（遺伝子組換え）サノフィ
- SwitzerlandAlprolix
- CzechiaALPROLIXSwedish Orphan Biovitrum AB (publ), Stockholm
- SpainALPROLIX 1.000 UI POLVO Y DISOLVENTE PARA SOLUCION INYECTABLESwedish Orphan Biovitrum Ab (Publ)
- FinlandALPROLIXSwedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Alprolix
- Liechtenstein · Alprolix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/83d95ec1-73d0-47a4-bba2-ef680f6e8d6a GET /v1/drugs/83d95ec1-73d0-47a4-bba2-ef680f6e8d6a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver og væske til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Koagulasjonsfaktor IX",
"merkevare_id": "ID_98C7CED1-B884-4F64-AF49-DA97949BFCE2",
"name_form_strength": "Alprolix pulv+væske til inj oppl 3000 IU",
"prescription_group": "C"
}See everything about coagulation factor ix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.